2 results
Approved WMOCompleted
Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.
Approved WMOCompleted
Comparison of the additional blood pressure lowering effect of RFSD with that of the addition of spironolactone in patients with a persistant increased blood pressure despite treatment with three different antihypertensive agents.